公开(公告)号：US10544192B2

公开(公告)日：2020-01-28

申请号：US15623723

申请日：2017-06-15

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Stefano Colloca ,  Alfredo Nicosia ,  Riccardo Cortese, Sr. ,  Virginia Ammendola ,  Maria Ambrosio

IPC: C07K14/005 ,  A61K39/12 ,  A61K39/235 ,  C12N7/00 ,  C12N15/86 ,  A61K39/00 ,  A61K48/00

Abstract: The present invention relates to novel adenovirus strains with an improved seroprevalence. In one aspect, the present invention relates to isolated polypeptides of adenoviral capsid proteins such as hexon, penton and fiber protein and fragments thereof and polynucleotides encoding the same. Also provided is a vector comprising the isolated polynucleotide according to the invention and adenoviruses comprising the isolated polynucleotides or polypeptides according to the invention and a pharmaceutical composition comprising said vector, adenovirus, polypeptide and/or polynucleotide. The invention also relates to the use of the isolated polypeptides, the isolated polypeptides, the vector, the adenoviruses and/or the pharmaceutical composition for the therapy or prophylaxis of a disease.

公开(公告)号：US10532067B2

公开(公告)日：2020-01-14

申请号：US15725858

申请日：2017-10-05

Applicant: GLAXOSMITHKLINE BIOLOGICALS, SA

Inventor： Andrew Geall ,  Katrin Ramsauer ,  Gillis Otten ,  Christian Walter Mandl

IPC: A61K31/7088 ,  A61K39/12 ,  C12Q1/00 ,  A61K39/00

Abstract: RNA encoding an immunogen is co-delivered to non-immune cells at the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the same delivered RNA lead to two different effects, which interact to produce a strong immune response against the immunogen. The non-immune cells translate the RNA and express the immunogen. Infiltrating immune cells respond to the RNA by expressing type I interferons and pro-inflammatory cytokines which produce a local adjuvant effect which acts on the immunogen-expressing non-immune cells to upregulate major histocompatibility complex expression, thereby increasing presentation of the translated protein to T cells. The effects on the immune and non-immune cells can be achieved by a single delivery of a single RNA e.g. by a single injection.

公开(公告)号：US10441648B2

公开(公告)日：2019-10-15

申请号：US15643084

申请日：2017-07-06

Applicant: GLAXOSMITHKLINE BIOLOGICALS, SA

Inventor： Stéphane André Georges Godart ,  Amina Laanan ,  Dominique Ingrid Lemoine

IPC: A61K39/04 ,  A61K39/02 ,  A61K39/00

Abstract: Immunogenic compositions comprising an M72 related antigen, wherein the conductivity of the composition is 13 mS/cm or lower, or the concentration of salts of the composition is 130 mM or lower, and their use in medicine, are provided.

公开(公告)号：US20190290748A1

公开(公告)日：2019-09-26

申请号：US16363799

申请日：2019-03-25

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Marco SORIANI ,  Maria SCARSELLI ,  Nathalie NORAIS ,  Danilo GOMES MORIEL ,  Silvia ROSSI PACCANI

IPC: A61K39/102 ,  C07K14/285 ,  C12R1/21 ,  A61K39/02 ,  A61K39/095

Abstract: NTHI protein antigens have been identified and found to be conserved across several Haemophilus influenzae pathogenic strains. They have been isolated, cloned from a reference strain and tested for immunogenicity. Methods for immunization and vaccines derived thereof are also disclosed.

公开(公告)号：US10392424B2

公开(公告)日：2019-08-27

申请号：US15120674

申请日：2015-02-27

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Matthew Bottomley ,  Enrico Malito ,  Manuele Martinelli ,  Maria Scarselli

IPC: A61K39/095 ,  C07K14/22 ,  A61K39/00

Abstract: Modified meningococcal fHbp polypeptides with increased stability.

公开(公告)号：US10307374B2

公开(公告)日：2019-06-04

申请号：US15495066

申请日：2017-04-24

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Luis Brito ,  Michelle C. Archer ,  Andrew Geall ,  Derek O'Hagan ,  Manmohan Singh

IPC: A61K9/107 ,  A61K39/12 ,  A61K39/155 ,  A61K31/713 ,  A61K9/00 ,  A61K39/00

Abstract: This invention generally relates to cationic oil-in-water emulsions that can be used to deliver nucleic acid molecules, such as an RNA molecule. The emulsion particles comprise an oil core and a cationic lipid. The emulsion particles have an average diameter of about 80 nm to about 180 nm, and the emulsion have an N/P ratio of at least 1.1:1.

公开(公告)号：US20190144507A1

公开(公告)日：2019-05-16

申请号：US16114621

申请日：2018-08-28

Applicant: GLAXOSMITHKLINE BIOLOGICALS, SA

Inventor： Michael Franti ,  Anders Lilja ,  Rebecca Loomis ,  Peter Mason

IPC: C07K14/005 ,  C12N15/86 ,  A61K39/12

Abstract: This disclosure provides platforms for delivery of herpes virus proteins to cells, particularly proteins that form complexes in vivo. In some embodiments these proteins and the complexes they form elicit potent neutralizing antibodies. Thus, presentation of herpes virus proteins using the disclosed platforms permits the generation of broad and potent immune responses useful for vaccine development.

公开(公告)号：US10226524B2

公开(公告)日：2019-03-12

申请号：US15679910

申请日：2017-08-17

Applicant: GLAXOSMITHKLINE BIOLOGICALS, SA

Inventor： Vega Masignani ,  Marirosa Mora ,  Maria Scarselli

IPC: A61K39/085 ,  C07K14/31 ,  A61K39/00

Abstract: The invention provides proteins from Staphylococcus aureus including amino acid sequences and the corresponding nucleotide sequences. The proteins are useful for vaccines, immunogenic compositions, diagnostics, enzymatic studies and also as targets for antibiotics.

公开(公告)号：US10172928B2

公开(公告)日：2019-01-08

申请号：US15536132

申请日：2015-12-17

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Francesco Berti ,  Paolo Costantino ,  Maria Rosaria Romano

IPC: G01N1/18 ,  A61K39/09 ,  C08B37/00

Abstract: A purification method for the capsular polysaccharide of type II GBS in which the capsular polysaccharide is filtered using a membrane with a cut-off of less than 30 kDa.

公开(公告)号：US20180354996A1

公开(公告)日：2018-12-13

申请号：US16023164

申请日：2018-06-29

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Normand Blais ,  Cindy Castado ,  Patrick Chomez ,  Marianne Dewerchin

IPC: C07K14/21 ,  A61K39/104 ,  A61K39/102 ,  C07K16/12 ,  A61K39/00

Abstract: The present invention relates to compositions comprising Moraxella catarrhalis (M. catarrhalis) Ubiquitous surface protein A2 (UspA2). More particularly, the present application relates to UspA2 protein constructs and immunogenic compositions comprising the constructs, vaccines comprising such immunogenic compositions and therapeutic uses of the same. The invention further relates to compositions comprising UspA2 in combination with at least one antigen from Haemophilus influenzae, immunogenic compositions comprising the antigens, vaccines comprising such immunogenic compositions and therapeutic uses of the same.